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Background: Metastatic colorectal cancer (mCRC) is a heterogeneous disease where prognosis is dependent both on tumor
biology and host factors. Total circulating cell-free DNA (cfDNA) has shown to harbor prognostic information in mCRC, although
less is known about the biological correlates of cfDNA levels in this patient group. The primary objective was to evaluate the
prognostic value of pretreatment cfDNA in patients receiving the first-line oxaliplatin-based chemotherapy for mCRC, by using a
predefined upper limit of normal (ULN) from a cohort of presumed healthy individuals. The secondary objective was to model
cfDNA levels as a function of predefined tumor and host factors.
Patients and methods: This was a retrospective post hoc study based on a prospective multicenter phase III trial, the NORDIC-
VII study. DNA was purified from 547 plasma samples and cfDNA quantified by a droplet digital PCR assay (B2M, PPIA) with
controls for lymphocyte contamination. Main clinical end point was overall survival (OS).
Results: cfDNA was quantified in 493 patients, 54 were excluded mainly due to lymphocyte contamination. Median cfDNA
level was 7673 alleles/ml (1050–1 645 000) for B2M and 5959 alleles/ml (555–854 167) for PPIA. High cfDNA levels were
associated with impaired outcome; median OS of 16.6 months for levels above ULN and 25.9 months for levels below ULN
(hazard ratio¼ 1.83, 95% confidence interval 1.51–2.21, P< 0.001). The result was confirmed in multivariate OS analysis
adjusting for established clinicopathological characteristics. A linear regression model predicted cfDNA levels from sum of
longest tumor diameters by RECIST, the presence of liver metastases and systemic inflammatory response as measured by
interleukin 6 (F(6, 357)¼ 62.7, P< 0.001).
Conclusion: cfDNA holds promise as a minimally invasive and clinically relevant prognostic biomarker in mCRC before
initiating first-line oxaliplatin-based chemotherapy and may be a complex entity associated with tumor burden, liver metastases
and systemic inflammatory response.
Trial registration: ClinicalTrials.gov, NCT00145314.
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Introduction
Colorectal cancer is the third most common cancer worldwide,
with over 1.8 million new cases and 881 000 deaths every year [1].
Combination chemotherapy is the preferred first-line treatment
of metastatic colorectal cancer (mCRC) [2]. Adding anti-epider-
mal growth factor receptor therapy may provide further clinical
benefit in RAS wild-type [3] and in particular left-sided RAS
wild-type cancers [4]. mCRC is a heterogeneous disease where
prognosis depends both on tumor biology and host factors [5].
There is a need for reliable biomarkers that can aid in clinical de-
cision making throughout the patient’s disease trajectory; select-
ing patients for optimal oncological and surgical strategies.
Small fragments of total circulating cell-free DNA (cfDNA)
can be detected in the blood stream of humans in health and dis-
ease [6, 7]. cfDNA originate primarily from cell turnover repre-
senting cells dying from apoptosis and necrosis [8] and can
readily be detected in patients with advanced cancers [7, 9] and
diseases driven by inflammatory processes [10, 11]. cfDNA has a
short biological half-life and sampling is minimally invasive,
making it an attractive biomarker at multiple decision points.
A negative prognostic significance of elevated cfDNA in
patients with mCRC has been described [12, 13]. The prognostic
role has mainly been investigated in patients before second and
subsequent lines of chemotherapy. It is uncertain if results are
transferable to a first-line setting. Most studies lack external val-
idation and no reference levels have been established.
Details regarding the release and possible biological correlates
of cfDNA in mCRC still remain unclear. There is an association
between tumor burden and cfDNA in human xenograft models
[14]. In what way other tumor characteristics influence cfDNA
levels is uncertain. Since cfDNA is released from both malignant
and non-malignant cells, we hypothesized that additional host
factors including systemic inflammatory response may further at-
tenuate cfDNA levels.
The primary objective was to evaluate the prognostic value of
cfDNA levels in plasma from mCRC patients before initiating
first-line oxaliplatin-based chemotherapy, by using a predefined
upper limit of normal (ULN) from a cohort of presumed healthy
individuals. cfDNA was assessed alone and in combination with
established prognostic clinicopathological and biochemical char-
acteristics used in daily clinical practice [15]. The secondary ob-
jective was to model cfDNA levels in mCRC patients as a function
of predefined tumor and host factors.
Patients and methods
Study designs
We used a retrospective post hoc study design based on a prospective
multicenter phase III trial, the NORDIC-VII study (NCT00145314), of
which the design, conduct and overall results have been reported [16]. In
short, NORDIC-VII investigated the effects of combining cetuximab
with the Nordic FLOX regimen with bolus 5-fluorouracil/folinic acid and
oxaliplatin in the first-line therapy of mCRC. There were no statistically
significant differences in outcome between the treatment arms [16, 17];
in the present study, data were analyzed across all arms. Clinical end
points were progression-free survival (PFS) and overall survival (OS),
additionally overall response rate (ORR) and number of patients with
complete surgical resection of metastases during the study period.
Description of tumor tissue RAS/BRAF mutation analyses and biochem-
ical serum analyses for alkaline phosphatase (ALP), carcinoembryonic
antigen (CEA) and interleukin 6 (IL-6) is specified in supplementary
Methods, available at Annals of Oncology online.
Clinicopathological characteristics
Clinicopathological characteristics were included as recommended for
phase III trials of systemic treatment in mCRC [15], which in this study
included location of primary tumor, resection status of primary tumor,
synchronous versus metachronous metastases, number of metastatic
sites, metastatic location, tumor tissue RAS/BRAF mutation status, age,
gender, body mass index and WHO performance status. Sidedness of pri-
mary tumor was assigned retrospectively for a subset of patients as
described in supplementary Methods, available at Annals of Oncology
online.
cfDNA purification and quantification
cfDNA was purified from 480 ml of EDTA-plasma and quantified by
droplet digital PCR (ddPCR) using a multiplex assay of gPPIA (132 base
pair amplicon) of the peptidylprolyl isomerase A gene (PPIA) and gB2M
(72 base pair amplicon) of the beta-2-microglobulin gene (B2M) as
described in supplementary Methods, available at Annals of Oncology
online.
Control for lymphocyte contamination
A ddPCR assay for detecting immunoglobulin heavy chain rearrange-
ments in B cells was carried out in duplicates for all samples as described
in supplementary Methods, available at Annals of Oncology online.
Defining ULN for cfDNA in a healthy cohort
The cohort of presumed healthy individuals consisted of random plasma
samples (N¼ 93) from the Lolland-Falster Health Study
(NCT02482896). The ULN of gPPIA was estimated to be 4663 alleles/ml
plasma and the ULN of gB2M was 6418 alleles/ml plasma (see supple-
mentary Methods, available at Annals of Oncology online).
Statistical analyses
Values were summarized as median and range for continuous variables
and proportions and percentages for categorical variables. Blood analyte
levels were not normally distributed and hence log transformed. Levels in
different groups were statistically compared using the one-way analysis
of variance. Correlations were investigated using the Spearman’s rho test.
Associations between categorical variables were evaluated using the chi-
square test.
The prognostic value of cfDNA level was initially assessed by log-rank
test and unadjusted univariate Cox proportional hazards model.
Clinicopathological characteristics, CEA and ALP were evaluated for
their prognostic value in combination with cfDNA in bivariate and sub-
sequent multivariate analyses.
A linear regression model was established to predict cfDNA levels
from clinicopathological characteristics, systemic inflammatory response
(SIR) as reflected by IL-6 and sum of longest tumor diameters (SLD) at
baseline by RECIST 1.0 [16]. Explanatory variables were arranged
belonging to the domains of tumor burden (N¼ 3), tumor characteris-
tics (N¼ 8) and host characteristics (N¼ 5). A similar logistic regression
model was established to assess the likelihood of having cfDNA above
ULN.
Univariate, bivariate or multivariate regression models refer to regres-
sion analyses with one, two or multiple explanatory variables, respectively.
Explanatory variables in multivariate regression models were chosen
using a stepwise approach, including significant covariates in models
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with one or two covariates. An unadjusted P-value threshold of P< 0.003
was used to call significance, corresponding to a Bonferroni adjusted
P< 0.05 after correction for N¼ 16 comparisons.
Statistical analyses were computed using SPSS version 25 (IBM Corp.,
Armonk, NY) and R version 3.5.0 (R Foundation for Statistical
Computing, Vienna, Austria). Results are reported according to the
Recommendations for Tumor Marker Prognostic Studies (REMARK)
checklist.
Ethics
The NORDIC-VII study and the Lolland-Falster Health Study were
approved by the national ethics committees and governmental authorities
in each country and conducted in accordance with the Declaration of
Helsinki. All patients and healthy donors gave written informed consent.
Results
Methodological considerations
The median and range of cfDNA as measured by gPPIA was 5959
alleles/ml plasma (555–854 167), whereas there was a tendency of
higher values as measured by gB2M with a median of 7673 alleles/
mL plasma (1050–1 645 000). The two measures were strongly
correlated (Spearman’s rho 0.98, P< 0.001). Hence, further stat-
istical analyses used the level of cfDNA as measured by gB2M due
to high correlation to gPPIA and lower detection limit. Results
indicate that some patients have gained a PPIA allele or lost a
B2M allele which could affect cfDNA count, details are specified
in supplementary Results, available at Annals of Oncology online.
Patient characteristics and cfDNA levels
cfDNA was quantified in 547 baseline samples. Fifty-three samples
were excluded due to contamination of lymphocytes and one sam-
ple due to failed ddPCR assay, leaving 493 patients with a valid re-
sult for further analyses (Figure 1). Clinicopathological and
biochemical characteristics of relevant cohorts are presented in
supplementary Table S1, available at Annals of Oncology online.
Elevated cfDNA levels were associated with poor performance
status, intact primary tumor, synchronous disease, liver metasta-
ses and elevated levels of CEA and ALP (P< 0.001; Table 1).
There was no statistically significant association with respect to
age, gender, body mass index, location of primary tumor (colon
versus rectum), sidedness of primary tumor (right versus left),
number of metastatic sites, RAS/BRAF tumor mutation status or
treatment arms (Table 1; supplementary Table S2, available at
Annals of Oncology online).
Clinical outcome and cfDNA levels
High cfDNA levels were associated with impaired outcome, with
median PFS of 7.7 months for levels above ULN and 8.3 months
for levels below ULN (hazard ratio¼ 1.43, 95% confidence inter-
val 1.18–1.73, P< 0.001) and median OS of 16.6 for levels above
ULN and 25.9 months for levels below ULN (hazard ratio¼ 1.83,
95% confidence interval 1.51–2.21, P< 0.001). Results were com-
parable when using an external ULN or internal cohort quartiles
(Figure 2). The same prognostic OS trend was observed when
stratifying for RAS/BRAF mutation status (supplementary Figure
S1, available at Annals of Oncology online). The independent
prognostic role of cfDNA was confirmed in bivariate (supple-
mentary Table S3, available at Annals of Oncology online) and a
subsequent multivariate Cox model for OS (Table 2).
Numerically more secondary metastasectomies were seen in
patients with cfDNA levels below ULN (N¼ 23/213, 10.8%) than
in patients with levels above ULN (N¼ 16/280, 5.7%, P¼ 0.04),
although the result did not reach the adjusted significance thresh-
old. Confirmed ORR did not differ between patients with cfDNA
levels below versus above ULN (N¼ 90/213, 42.3% versus
N¼ 137/280, 48.9%, P¼ 0.14).
Modelling cfDNA levels as a function of 16
predefined variables belonging to the domains of
tumor burden, tumor characteristics and host
characteristics
Regression models were established as described in Figure 3. Six
of the explanatory variables remained significantly associated
with cfDNA in univariate regression analyses. A multivariate lin-
ear regression model significantly predicted cfDNA levels from
SLD by RECIST, the presence of liver metastases and SIR as meas-
ured by IL-6. These variables in combination accounted for 51%
of the explained variability (F(6, 357)¼ 62.7, P< 0.001), and rep-
resented each predefined domain (supplementary Table S4, avail-
able at Annals of Oncology online). A multivariate logistic
regression model identified the same variables to significantly ac-
count for the likelihood of having cfDNA above ULN (supple-
mentary Table S5, available at Annals of Oncology online;
Figure 3C).
Discussion
We have previously reported in a meta-analysis that high cfDNA
levels are associated with poor prognosis in mCRC [13]. The
meta-analysis included 10 variously sized cohorts, mainly report-
ing data before second or subsequent treatment lines. We hereby
confirm these findings in a large cohort before initiating first-line
Total cohort (N = 566)
Patients analyzed for
baseline cfDNA (N = 547)
cfDNA cohort (N = 493)
cfDNA and tissue
cohort (N = 397)
Blood samples at baseline
not available (N = 19)
Lymphocyte contamination
or assay failure (N = 54)
Tumor RAS/BRAF mutation
status unknown (N = 96)
cfDNA, tissue and
IL-6 cohort (N = 364)
Serum interleukin 6 (IL-6)
status unknown (N = 33)
Figure 1. CONSORT diagram.
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treatment. The long-term follow-up of this study (median
exceeding 7 years) furthermore enabled us to show that normal
cfDNA levels predict long-term survival in this patient group (5-
year survival rate 17%) compared with patients with elevated
levels (5-year survival rate 4.5%). We identified numerically
more metastatectomies in patients with normal cfDNA upfront,
suggesting an enrichment of patients fit for surgery with limited
tumor burden in this group. Based on these findings, we suggest
Table 1. Total circulating cell-free DNA (cfDNA) levels (alleles/ml plasma) as measured by gPPIA and gB2M for different clinicopathological characteristics in
the cfDNA cohort (N 5 493) of patients with mCRC
Characteristics gPPIA, median (IQR),
alleles/ml




Below median 6083 (18 417) 0.835 7750 (18 917) 0.856
Above median 5938 (17 108) 7663 (19 420)
Gender
Male 6167 (19 571) 0.552 7712 (20 676) 0.760
Female 5917 (16 166) 7489 (17 566)
Body mass index
<18.5 7958 (8314) 0.053 9208 (11 850) 0.115
18.5–24.9 6633 (28 125) 8375 (27 813)
25.0–29.9 6167 (18 387) 7837 (18 500)
30 4783 (4441) 6292 (6057)
WHO performance status
0 5011 (11 619) <0.001 6625 (12 560) <0.001
1–2 11 167 (38 449) 15 500 (43 206)
Location primary tumor
Colon 6612 (19 500) 0.134 9366 (21 222) 0.038
Rectum 5083 (14 660) 6515 (15 826)
Sidedness primary tumora
Right 6333 (10 500) 0.436 8500 (12 583) 0.788
Left 5125 (14 833) 6845 (16 729)
Resection status primary tumor
Resected 4333 (9324) <0.001 6042 (12 080) < 0.001
Not resected 13 417 (56 182) 16 833 (60 625)
Time of metastases
Synchronous 7667 (29 639) <0.001 9702 (31 012) <0.001
Metachronous 3625 (5872) 5277 (7638)
Number of metastatic sites
1 site 5366 (11 917) 0.168 6809 (12 592) 0.101
>1 site 6250 (21 748) 8000 (21 614)
Metastatic location
Non-liver 3083 (3256) <0.001 4291 (4590) <0.001
Liver þ other site 8681 (32 073) 10 833 (34 917)
Liver only 9047 (27 688) 10 750 (27 850)
Tissue mutation statusb
RAS/BRAF wild-type 6417 (17 245) 0.060 7917 (16 333) 0.133
RAS mutation 4589 (9454) 6542 (12 395)
BRAF mutation 4986 (11 622) 7241 (14 780)
Alkaline phosphatase
Below ULN 3417 (3781) <0.001 5082 (4713) <0.001
Above ULN 18 667 (53 390) 20 500 (53 679)
Carcinoembryonic antigenc
Below ULN 3250 (2917) <0.001 4833 (3917) <0.001
Above ULN 7333 (25 301) 9667 (27 167)
Levels in different groups were statistically compared using the analysis of variance test with log transformed values.
aSidedness primary tumor analyzed for N¼ 363 patients.
bTissue mutation status analyzed for N¼ 397 patients.
cCarcinoembryonic antigen analyzed for N¼ 492 patients.
IQR, interquartile range; ULN, upper limit of normal.
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that cfDNA measured at baseline reflects fundamental aspects of
the tumor and host, rather than predicting the effect of first-line
chemotherapy.
Increased cell death and damaged vasculature due to tumor
invasiveness may both be relevant underlying processes leading
to increased cfDNA. Thus, tumor burden is commonly regarded
as a major factor influencing cfDNA, although there is no consen-
sus on how ‘burden’ should be measured. An experimental model
using nude mice xenografted with human CRC cells indeed
showed increasing cfDNA with increasing tumor weight [18].
Human studies on local/locally advanced disease indicate that
surgical removal of the primary tumor results in lower cfDNA
levels [19]. However, the data are conflicting in a metastatic set-
ting. One study on advanced lung cancer found no significant
correlation between cfDNA and metabolic tumor volume or total
lesion glycolysis as estimated by positron emission tomography/
computed tomography [20]. Others have found that baseline
cfDNA levels in treatment naive mCRC patients correlate with
radiologic disease burden, but this trend could not be observed at
time of disease progression and subsequent therapy lines [21].
We established multiple regression models and identified that
cfDNA level variability in mCRC can be explained partly by tumor
burden, but also by other characteristics of tumor and host. Our
findings support that the presence of liver metastases is associated
with high cfDNA levels, which could partly be independent from
tumor burden. Sprouting angiogenesis with dysfunctional and
leaky vasculature is common in liver metastases, and could be a
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Figure 2. Clinical outcome of patients in the cfDNA cohort (N¼ 493). Progression-free survival as stratified according to total circulating cell-
free DNA (cfDNA) below and above upper limit of normal (ULN) (A) and quartiles (B). Overall survival as stratified according to cfDNA below
and above ULN (C) and quartiles (D). CI, confidence interval.
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In contrast, lung and lymph node metastases more often hijack
existing well-functioning vasculature by co-option [23, 24].
Furthermore, we confirm an association between cfDNA and
SIR as measured by IL-6. In non-malignant disease there is a posi-
tive correlation between cfDNA levels and inflammatory states
[10, 11]. An acute phase response increases local and/or systemic
vascular permeability, which intuitively could make cell debris
including DNA rapidly appear in the blood circulation. Contrary,
studies have mechanistically suggested that endogenous cfDNA
may enhance an innate immune response through activation of
toll-like receptor 9 in dendritic cells, monocytes and macro-
phages [10, 25]. Despite a strong association in our study, we can-
not conclude on a causal or temporal relationship between
cfDNA and IL-6/SIR in patients with mCRC.
Our quest for factors influencing cfDNA level variability was
limited to the parameters available within the framework of a
phase III clinical trial. Variables within the categories tumor bur-
den, tumor characteristics and host characteristics are surrogate
markers, with certain overlaps and interactions as highlighted in
our analyses. As an example, tumor burden as characterized by
RECIST is a rather crude measure and could add uncertainty to
our predictions. Furthermore, the molecular orchestra mediating
SIR in colorectal cancer patients is complex. We chose circulating
IL-6 as a marker since it has been proposed as one of the key
mediators of SIR in mCRC as a result of tumor necrosis [26, 27].
Still this is a simplification of reality, and other markers could
have strengthened predictions and complemented interpreta-
tions. Despite these limitations, our final multivariate model
identified one factor from each domain explaining more than
half of the observed cfDNA level variability in mCRC patients.
Our findings suggest a relationship between cfDNA and tumor
burden, the presence of liver metastases, and SIR, all of which are
modes associated with poor prognosis in mCRC. There could
also be a more direct link between cfDNA, tumor biology and
prognosis. A recent CRC cell line study found that the presence of
DNA in the tumor microenvironment promotes tumor cell sur-
vival after cytotoxic insults, through induction of autophagy
[28]. This suggests that cfDNA could exert a disease-modulating
biological function and not only be an innocent bystander.
Further pre-clinical and clinical studies are needed to understand
the different facets of cfDNA, both as a complex biomarker and
potential target during mCRC treatment.
There are several potential clinical implications of our findings.
High cfDNA predicts poor survival in mCRC, and patients with
high cfDNA fit for therapy may potentially benefit from a more
intensive first-line regimen (i.e. triplet chemotherapy;
FOLFOXIRI). One of the keys of ensuring appropriate patient se-
lection for metastasectomy is prediction of long-term survival,
but current risk scores lack sufficient discriminatory accuracy
[29]. Given that normal cfDNA predicts long-term survival,
cfDNA could potentially improve established risk scores used for
stratifying patients based on their likelihood of recurrence.
Despite the fact that the prognostic utility of cfDNA looks prom-
ising, its clinical usefulness must be validated in prospective clin-
ical trials.
Conclusion
cfDNA at baseline is a strong prognostic factor for mCRC before
initiating first-line oxaliplatin-based chemotherapy, even when
adjusting for established clinicopathological and biochemical
prognostic markers. Our findings indicate that cfDNA may be a
complex marker for tumor burden, the presence of liver metasta-
ses and SIR, and that it holds promise as a clinically relevant prog-
nostic biomarker in mCRC.
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Table 2. Adjusted multivariate Cox regression model for overall survival in
the cfDNA and tissue cohort (N 5 397) including total circulating cell-free
DNA (cfDNA) level as measured by gB2M and other prognostic variables
significant in bivariate analyses
HR L 95% CI U 95% CI P value
WHO performance status
0 (N ¼ 269) 1
1–2 (N ¼ 128) 1.64 1.31 2.06 <0.001
Tissue mutation status
RAS/BRAF wild type (N ¼ 171) 1
RAS mutation (N ¼ 182) 1.55 1.24 1.93 <0.001
BRAF mutation (N ¼ 44) 4.50 3.13 6.46 <0.001
Alkaline phosphatase
ALP below ULN (N ¼ 211) 1
ALP above ULN (N ¼ 186) 1.71 1.35 2.16 <0.001
Carcinoembryonic antigen
CEA below ULN (N ¼ 69) 1
CEA above ULN (N ¼ 328) 1.47 1.08 2.01 0.015
cfDNA level
gB2M below ULN (N ¼ 182) 1
gB2M above ULN (N ¼ 215) 1.54 1.21 1.96 <0.001
HR, hazard ratio; L, lower; U, upper; CI, confidence interval; ULN, upper
limit of normal.
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Figure 3. Modelling total circulating cell-free DNA levels as a function of 16 predefined variables. Linear and logistic regression models were
established to investigate relationships between cfDNA levels and 16 predefined variables belonging to the domains of tumor burden, tumor
characteristics and host characteristics of patients in the cfDNA, tissue and IL-6 cohort (N¼ 364). Variables of tumor burden (N¼ 3) include resec-
tion status of primary tumor, number of metastatic sites and sum of longest tumor diameters (SLD) by RECIST; tumor characteristics (N¼ 8) in-
clude location of primary tumor, tumor RAS and BRAF mutation status, time of metastases, and metastatic involvement of the liver, lung, lymph
nodes and peritoneum; host characteristics (N¼ 5) include age, gender, body mass index (BMI), WHO performance status and systemic inflam-
matory response (SIR) as reflected by serum level of interleukin 6 (IL-6) (A). Collinearity between explanatory variables used in the models is illus-
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